Motus GI readies for US launch of colonoscopy prep system — 4 insights

Motus GI reported a net loss of $5.7 million in the second quarter of 2019, but is readying for the inpatient commercial launch of its colonoscopy preparation system Pure-Vu.

What you should know:

1. For the quarter, Motus reported clinical results from its latest study — showing that the Pure-Vu system increased bowel preparation rates from a baseline of 38 percent to 96 percent. The Pure-Vu system is a device used during colonoscopy to clean a poorly prepared colon. The company also received FDA 510(k) clearance for the Pure-Vu and made several appointments to bolster its leadership staff.

2. Motus' next near-term milestone is the commercial launch of the Pure-Vu system. The company has not yet specified when the launch will occur.

3. For the year to date, Motus has posted a net loss of $12 million.

4. Motus has $13.8 million in assets through the second quarter and $22.95 million in assets through the year to date.

Read the entire source here.

More articles on surgery centers: 
6 spine-focused ASCs opened or announced this year
The 10 best states for healthcare l 2019
Physician-managed Altair Health opens spine ASC — 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers